KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Current Assets (2018 - 2025)

Adaptive Biotechnologies' Current Assets history spans 8 years, with the latest figure at $300.2 million for Q4 2025.

  • For Q4 2025, Current Assets rose 5.79% year-over-year to $300.2 million; the TTM value through Dec 2025 reached $300.2 million, up 5.79%, while the annual FY2025 figure was $300.2 million, 5.79% up from the prior year.
  • Current Assets for Q4 2025 was $300.2 million at Adaptive Biotechnologies, up from $281.4 million in the prior quarter.
  • Across five years, Current Assets topped out at $765.0 million in Q1 2021 and bottomed at $256.5 million in Q1 2025.
  • The 5-year median for Current Assets is $414.7 million (2022), against an average of $425.2 million.
  • The largest annual shift saw Current Assets plummeted 46.77% in 2021 before it surged 39.58% in 2022.
  • A 5-year view of Current Assets shows it stood at $402.7 million in 2021, then soared by 39.58% to $562.1 million in 2022, then fell by 27.03% to $410.2 million in 2023, then plummeted by 30.82% to $283.8 million in 2024, then grew by 5.79% to $300.2 million in 2025.
  • Per Business Quant, the three most recent readings for ADPT's Current Assets are $300.2 million (Q4 2025), $281.4 million (Q3 2025), and $261.9 million (Q2 2025).